New global criteria for pediatric CNO aim to boost research & improve care for this rare autoinflammatory bone disease.
Search results for: infliximab
Cardiovascular Risks Similar for JAK Inhibitors & bDMARDs
Using data from registries across Europe and Canada, Aymon et al. compared the incidence of major adverse cardiac events (MACE) in patients with RA treated with JAK inhibitors, TNF inhibitors or biologic DMARDs with other modes of action over two years. The researchers did not find an increased risk of MACE with JAK inhibitors over that time frame.
Medicare Drug Price Negotiation: What ACR Members Need to Know Ahead of Round Three
As the program enters its third round of negotiations, ACR members should be aware of several upcoming changes relevant to rheumatology.
August Updates from the ACR Insurance Subcommittee
The Insurance Subcommittee of the Committee on Rheumatologic Care is working on behalf of ACR members to address critical coverage and reimbursement challenges.
The Long Silk Road
Matteo Piga, MD, highlighted the latest research into Behçet’s disease, including developments into the understanding of its pathophysiology and positive results for potential treatments.
Aetna Implements Specialty Pharmacy Requirements
On July 1, Aetna launched its new Combined Benefit Management Drug List, effectively moving romosozumab-aqqg (Evenity) and infliximab (Remicade) to pharmacy-only coverage for most fully insured commercial plans. The ACR has contacted Aetna leaders to raise concerns about patient access to these therapies.
ACR-Led Resolutions Supporting Research Funding, Biosimilars Access Advance at Annual AMA House of Delegates Meeting
An ACR-led resolution that calls for the protection of NIH funding and the ability to negotiate indirect costs will become AMA policy, along with several other resolutions supported by the ACR.
New Analysis Reveals More Potential Contributors to Takayasu Arteritis
Recent research led to development of a cumulative genetic risk score for Takayasu arteritis, identifying differing susceptibility between groups with different genetic ancestries.
ACR Responds to Aetna Specialty Pharmacy Requirements
Aetna recently notified practices about the launch of its Combined Benefit Management Drug List, which will result in romosozumab-aqqg (Evenity) and infliximab (Remicade) moving to pharmacy-only coverage on July 1. The ACR is working to oppose this change.
Underwater Biosimilars Coalition Shares Results of Practice Survey with Congressional Leaders
This week, the Coalition sent Congressional leadership a letter detailing the results of a recent survey about how underwater biosimilars are impacting physicians’ ability to provide high-quality care. Almost all of the nearly 200 practices queried reported being underwater on several biosimilars, with rituximab and infliximab biosimilars being the most common.
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 41
- Next Page »